Works Cited

Migraine: Diagnosis and Therapeutic Advances

Course #90072 - $30 -

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.

1. Fuh JL, Wang SJ, Lu SR, Liao YC, Chen SP, Yang CY. Headache disability among adolescents: a student population-based study. Headache. 2010;50(2):210-218.

2. Rasmussen BK. Epidemiology of headache. Cephalalgia. 2001;21(7):774-777.

3. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210.

4. Goldstein JN, Camargo CA, Pelletier AJ, Edlow JA. Headache in United States emergency departments: demographics, work-up and frequency of pathological diagnoses. Cephalalgia. 2006;26(6):684-690.

5. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and need for preventive therapy. Neurology. 2007;68(5):343-349.

6. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004;24(Suppl 1):9-160.

7. Eller M, Goadsby PJ. MRI in headache. Expert Rev Neurother. 2013;13(3):263-273.

8. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.

9. Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. Neurology. 2004;63(3):427-435.

10. Crosby SJ. Headache. In: Zeind CS, Carvalho MG (eds). Applied Therapeutics: The Clinical Use of Drugs. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2018: 1233-1245.

11. Schwedt TJ. Thunderclap headaches: a focus on etiology and diagnostic evaluation. Headache. 2013;53(3):563-569.

12. Edlow JA, Panagos PD, Godwin SA, Thomas TL, Decker WW. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute headache. Ann Emerg Med. 2008;52(4):407-436.

13. Savitz SI, Levitan EB, Wears R., Edlow JA. Pooled analysis of patients with thunderclap headache evaluated by CT and LP: is angiography necessary in patients with negative evaluations? J Neurol Sci. 2009;276(1-2):123-125.

14. Halker RB, Vargas BB. Primary exertional headache: updates in the literature. Curr Pain Headache Rep. 2013;17(6):1-4.

15. Cady RK, Farmer K. Migraine. In: Jay GW (ed). Clinician's Guide to Chronic Headache and Facial Pain. New York, NY: Informa Healthcare USA; 2010: 1-15.

16. Khouri CK, Couch JR. Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. Drug Des Devel Ther. 2010;18(4):9-17.

17. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-657.

18. Hershey A. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 2010;9(2):120-204.

19. Winner P. Epidemiology of pediatric headache. In: Hershey AD, Powers SW, Winner P, Kabouche M (eds). Pediatric Headaches in Clinical Practice. Chichester: John Wiley & Sons, Ltd.; 2009: 31-39.

20. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-976.

21. World Health Organization. Lifting the Burden: Atlas of Headache Disorders and Resources in the World, 2011. Available at Last accessed June 15, 2021.

22. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609.

23. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106(1-2):81-89.

24. Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456-1470.

25. Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76(8):711-718.

26. Headache Classification Committee, Olesen J, Bousser MG, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26(6):742-746.

27. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine: classification, characteristics and treatment. Nat Rev Neurol. 2012;8(3):162-171.

28. Wolff HG. Headache and Other Head Pain. 2nd ed. New York, NY: Oxford University Press; 1963.

29. Cutrer FM. Pathophysiology of migraine. Semin Neurol. 2010;30(2):120-130.

30. De Hoon JNJM. Migraine and Antimigraine Drugs: Focus on Cardiovascular Aspects [Dissertation]. Maastricht: University of Maastricht; 2000.

31. Chapman LF, Ramos AO, Goodell H, Silverman G, Wolff HG. A humoral agent implicated in vascular headache of the migraine type. Arch Neurol. 1960;3:223-229.

32. Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol. 2012;8(2):89-99.

33. Sicuteri F, Renzi D, Geppetti P. Substance P and enkephalins: a creditable tandem in the pathophysiology of cluster headache and migraine. Adv Exp Med Biol. 1986;198(Pt B):145-152.

34. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12(10):570-584.

35. Messlinger K, Fischer MJM, Lennerz JK. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. Keio J Med. 2011;60(3):82-89.

36. Olesen J, Ashina M. Emerging migraine treatments and drug targets. Trends Pharmacol Sci. 2011;32(6):352-359.

37. Charles A, Brennan KC. Cortical spreading depression: new insights and persistent questions. Cephalalgia. 2009;29(10):1115-1124.

38. Eikermann-Haerter K, Ayata C. Cortical spreading depression and migraine. Curr Neurol Neurosci Rep. 2010;10(3):167-173.

39. Weir GA, Cader MZ. New directions in migraine. BMC Med. 2011;9:116.

40. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002;8(2):136-142.

41. Bowyer SM, Aurora KS, Moran JE, Tepley N, Welch KM. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol. 2001;50(5):582-587.

42. D'Esposito M, Deouell LY, Gazzaley A. Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging. Nat Rev Neurosci. 2003;4(11):863-872.

43. Woods RP, Iacobini M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med. 1994;331(25):1689-1692.

44. Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury.J Cereb Blood Flow Metab. 2011;31(1):17-35.

45. Goadsby PJ, Charbit AR, Anreou AP, Akerman S, Holland PR. Neurobiology of migraine. Neuroscience. 2009;161(2):327-341.

46. Goadsby PJ, Raskin NH. Headache. In: Jameson J, Fauci A, Kasper D, Hauser S, Longo D, Loscalzo J (eds). Harrison's Principles of Internal Medicine. 20th ed. McGrawHill; New York, NY: 2018.

47. Holland PR. Modulation of trigeminaovascular processing: novel insights into primary headache disorders. Cephalalgia. 2009:29(Suppl 3):1-6.

48. Alonso AA, Nixdorf DR. Case studies of four different headache types presenting as tooth pain. J Endod. 2006;32(11):1110-1113.

49. Cady RK, Schreiber CP. Sinus problems as a cause of headache refractoriness and migraine chronification. Curr Pain Headache Rep. 2009;13(4):319-325.

50. Eross E, Dodick D, Eross M. The sinus, allergy and migraine study (SAMS). Headache. 2007;47(2);213-224.

51. Obermann M, Mueller D, Yoon M-S, Pageler L, Diener HC, Katsarava Z. Migraine with isolated facial pain: a diagnostic challenge. Cephalalgia. 2007;27(11):1278-1282.

52. Lança AJ. Functional and neurochemical organization of the central nervous system. In: Kalant H, Grant DM, Mitchell J (eds). Principles of Medical Pharmacology. 7th ed. Toronto: Elsevier; 2007: 187-210.

53. Haydon PG, Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev. 2006;86(3):1009-1031.

54. Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci. 2008;28(46):11768-11777.

55. Rogawski MA. Common patholophysiologic mechanisms in migraine and epilepsy. Arch Neurol. 2008;65(6):709-714.

56. Waxman SG. Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype. Nat Neurosci. 2007;10(4):405-409.

57. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010;9(4):413-424.

58. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia. 2007;27(11):1295-1300.

59. Schwedt TJ. Serotonin and migraine: the latest developments. Cephalalgia. 2007;27(11):1301-1307.

60. Barra S, Lanero S, Materazzi C, Vitagliano G, Ames PR, Gaeta G. Sumatriptan therapy for headache and myocardial infarction. Expert Opin Pharmacother. 2010;11(16):2727-2737.

61. Gupta S, Nahas SJ, Peterlin BL. Chemical mediators of migraine: preclinical and clinical observations. Headache. 2011;51(6):1029-1045.

62. Marmura MJ, Silberstein SD. Current understanding and treatment of headache disorders: five new things. Neurology. 2011;76(7 Suppl 2):S31-S36.

63. Schürks M. Genetics of migraine in the age of genome-wide association studies. J Headache Pain. 2012;13(1):1-9.

64. Minor DS, Harrell TK. Headache disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill; 2017: 927-942.

65. Burstein R, Jakubowski M, Rauch SD. The science of migraine. J Vestib Res. 2011;21(6):305-314.

66. Villalon CM, Olesen J. The role of CGTP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute migraine drugs. Pharmacol Ther. 2009;124(3):309-323.

67. Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. BMC Medicine. 2009;7:71.

68. Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P. Future drugs for migraine. Intern Emerg Med. 2009;4(5):367-373.

69. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372(9656):2115-2123.

70. Olesen J. Nitric oxide-related drug targets in headache. Neurotherapeutics. 2010;7(2):183-190.

71. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain. 2012;13(3):177-189.

72. Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine: the International Headache Society Task Force on combined oral contraceptives and hormone replacement therapy. Cephalalgia. 2000;20(3):155-156.

73. ACOG Committee on Practice Bulletins. ACOG practice bulletin no. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107(6):1453-1472.

74. Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346-1353.

75. de Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM. Molecular genetics of migraine. Hum Genet. 2009;126(1):115-132.

76. Barrett CF, van den Maagdenberg AM, Frants RR, Ferrari MD. Familial hemiplegic migraine. Adv Genet. 2008;63:57-83.

77. Cain SM, Snutch TP. Voltage-gated calcium channels and disease. Biofactors. 2011;37(3):197-205.

78. Gardner KL. Genetics of migraine: an update. Headache. 2006;46(Suppl 1):S19-S24.

79. Mulder EJ, Van Baal C, Gaist D, et al. Genetic and enviormental influences on migraine: a twin study across six countries.Twin Res. 2003;6(5):422-431.

80. Svennsson DA, Larsson B, Walsenlind E, Pedersen NL. Shared rearing enviroment in migraine: results from twins reared apart and twins reared together. Headache. 2003;43(3):235-244.

81. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9):1337-1342.

82. Charles A, Flippen C, Romero-Reyes M, Brennan KC. Memantine for prevention of migraine: a retrospective study of 60 cases.J Headache Pain. 2007;8(4):248-250.

83. Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura.Hum Genet. 2009;125(3):265-279.

84. Kelley NE, Tepper DE. Rescue therapy for acute migraine. Part 2: neuroleptics, antihistamines, and others. Headache. 2012;52(2):292-306.

85. Saguil A, Lax JW. Acute migraine treatment in emergency settings. Am Fam Physician. 2014;89(9):742-744.

86. Crawford P, Simmons M, Hoock J. What dietary modifications are indicated for migraines? J Fam Pract. 2006;55(1):62-63.

87. Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician. 2011;83(3):271-280.

88. Laine C, Goldmann D, Wilson JF. In the clinic: migraine. Ann Intern Med. 2007;147(5):ITC11-1-ITC11-16.

89. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.

90. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA. 2006;296(3):283-291.

91. Silberstein SD. Migraine. Lancet. 2004;363(9406):381-391.

92. Cutrer FM, Bajwa ZH, Sabahat A. Pathophysiology, clinical manifestations, and diagnosis of migraine in adults. UptoDate. 2012;17(3):1-23.

93. Sprenger T, Borsook D. Migraine changes the brain: neuroimaging makes its mark. Curr Opin Neurol. 2012;25(3):252-262.

94. Goadsby PJ. The migrainous brain: what you see is not all you get? PLoS Med. 2006;3(10):e404.

95. Granziera C, DaSilva AF, Snyder J, Tuch DS, Hadjikhani N. Anatomical alterations of the visual motion processing network in migraine with and without aura. PLoS Med. 2006;3(10):e402.

96. May A, Matharu M. New insights into migraine: application of functional and structural imaging. Curr Opin Neurol. 2007;20(3):306-309.

97. Moschiano F, D'Amico D, Di Stefano M, Rocca N, Bussone G. The role of the clinician in interpreting conventional neuroimaging findings in migraine patients. Neurol Sci. 2007;28(Suppl 2):S114-S117.

98. Dahlöf C, Maassen Van Den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan: basic science in relation to migraine treatment. Headache. 2012;52(4):707-714.

99. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41(7):638-645.

100. Cooke LJ, Becker WJ. Migraine prevalence, treatment and impact: the Canadian Women Migraine Study. Can J Neurol Sci. 2010;37(5):580-587.

101. Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache. 2009;49(Suppl 1):S21-S33.

102. Bigal ME. Migraine, lipid profile, and cardiovascular disease. Eur J Neurol. 2010;17(3):342-343.

103. Bond DS, Roth J, Nash JM, Wing RR. Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment. Obes Rev. 2011;12(5):362-371.

104. Gruber H-J, Bernecker C, Pailer S, et al. Lipid profile in normal weight migraineurs: evidence for cardiovascular risk. Eur J Neurol. 2010:17(3):419-425.

105. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol. 2008;7(4):354-361.

106. Sacco S, Cerone D, Carolei A. Comorbid neuropathologies in migraine: an update on cerebrovascular and cardiovascular aspects.J Headache Pain. 2008;9(4):237-248.

107. Silva IR, Freitas GR. Migraine patients should be cautiously followed for risk factors leading to cardiovascular disease. Arq Neuropsiquiatr. 2013;71(2):119-124.

108. Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(5):1545-1588.

109. Linde M, Stovner LJ, Zwart JA, Hagen K. Time trends in the prevalence of headache disorders: the Nord-Trondelag Health Studies (HUNT 2 and HUNT 3). Cephalalgia. 2011;31(5):585-596.

110. Matharu MS, Cohen AS, McGonigle DJ, Ward N, Frackowiak RS, Goadsby PJ. Posterior hypthalamic and brainstem activation in hemicrania continua. Headache. 2004;44(8):747-761.

111. Wallasch TM, Angeli A, Kropp P. Outcomes of a headache-specific cross-sectional multidisciplinary treatment program. Headache. 2012;52(7):1094-1105.

112. Edmeads J, Láinez JM, Brandes JL, Schoenen J, Freitag F. Potential of the Migraine Disability Assessment (MIDAS) questionnaire as a public health initiative and in clinical practice. Neurology. 2001;56(6 Suppl 1):S29-S34.

113. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20-S28.

114. Weaver-Agostini J. Cluster headache. Am Fam Physician. 2013;88(2):122-128.

115. Edvardsson B. Symptomatic cluster headache; a review of 63 cases. Springerplus. 2014;3:64-75.

116. Ferrante E, Tassorelli C, Rossi P, Lisotto C, Nappi G. Focus on the management of thunderclap headache: from nosography to treatment. J Headache Pain. 2011;12(2):251-258.

117. Moukhachen O, Grgurich P. Ischemic and hemorrhagic stroke. In: Zeind CS, Carvalho MG (eds). Applied Therapeutics: The Clinical Use of Drugs. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2018: 1301-1318.

118. Porter RS (ed). Neurologic disorders. In: Merck Manual of Diagnosis and Therapy. 20th ed. Whitehouse Station, NJ: MerckSharp & Dohme; 2018.

119. Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993;43(9):1678-1683.

120. Israel HA, Scrivani SJ. The interdisciplinary approach to oral, facial and head pain. J Am Dent Assoc. 2000;131(7):919-926.

121. Okeson JP, de Leeuw R. Differential diagnosis of temporomandibular disorders and other orofacial pain disorders. Dent Clin North Am. 2011;55(1):105-120.

122. Romero-Reyes M, Uyanik JM. Orofacial pain management: current perspectives. J Pain Res. 2014;7:99-115.

123. Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States.J Am Dent Assoc. 1993;124(10):115-121.

124. Graff-Radford SB. Facial pain, cervical pain, and headache. Continuum (Minneap Minn). 2012;18(4):869-882.

125. Klausner, JJ. Epidemiology of chronic facial pain: diagnostic usefulness in patient care. J Am Dent Assoc. 1994;125(12):1604-1611.

126. Mitrirattanakul S, Merrill RL. Headache impact in patients with orofacial pain. JADA. 2006;137(9):1267-1274.

127. Lupoli TA, Lockey RF, Temporomandibular dysfunction: an often overlooked cause of chronic headaches. Ann Allergy Asthma Immunol. 2007;99(4):314-318.

128. Germain L. Differential diagnosis of toothache pain. Part 1: odontogenic etiologies. Dent Today. 2012;31(7):92-97.

129. Nguyen DH, Martin JT. Common dental infections in the primary care setting. Am Fam Physician. 2008;77(6)797-802.

130. American Association of Endodontists. Use and Abuse of Antibiotics. Available at Last accessed June 15, 2021.

131. Simons DG, Travell JG, Simons LS. Travell & Simons' Myofascial Pain and Dysfunction: The Trigger Point Manual. 2nd ed. Baltimore, MD: Williams & Wilkins; 1999.

132. Koratkar H, Parashar V, Koratkar S. A review of neuropathic pain conditions affecting teeth. Gen Dent. 2010;58(5):436-441.

133. Marbach JJ, Raphael KG. Phantom tooth pain: a new look at an old dilemma. Pain Med. 2000;1(1):68-77.

134. Germain L. Differential diagnosis of toothache pain. Part 2: nonodontogenic etiologies. Dent Today. 2012;31(8):84-89.

135. Clark GT. Persistent orodental pain, atypical odontalgia, and phantom tooth pain: when are they neuropathic disorders? J Calif Dent Assoc. 2006;34(8):599-609.

136. Hersh EV, Balasubramaniam R, Pinto A. Pharmacologic management of temporomandibular disorders. Oral Maxillofac Surg Clin North Am. 2008;20(2):197-210.

137. Smith PF, Epstein JB. Orofacial pain. In: Davies AN, Epstein JB (eds). Oral Complications of Cancer and Its Management. Oxford: Oxford University Press; 2010: 241-251.

138. Feldt B, Gion GB, Weitzel EK, McMains KC. Acute sinusitis. South Med J. 2013;106(10):577-581.

139. Kamani T, Jones NS. 12 minute consultation: evidence based management of a patient with facial pain. Clin Otolaryngol. 2012;37(3):207-212.

140. Patel ZM, Kennedy DW, Setzen M, Poetker DM, DelGaudio JM. "Sinus headache:" rhinogenic headache or migraine? An evidence-based guide to diagnosis and treatment. Int Forum Allergy Rhinol. 2013;3(3):221-230.

141. Bamford CC, Mays M, Tepper SJ. Unusual headaches in the elderly. Curr Pain Headache Rep. 2011;15(4):295-301.

142. Langford CA, Fauci AS. The vasculitis syndromes. In: Jameson J, Fauci A, Kasper D, Hauser S, Longo D, Loscalzo J (eds).Harrison's Principles of Internal Medicine. 20th ed. New York, NY: McGraw-Hill: 2018.

143. Reiter S, Winocur E, Goldsmith C, Emodi-Perlman A, Gorsky M. Giant cell arteritis misdiagnosed as temporomandibular disorder: a case report and review of the literature. J Orofac Pain. 2009;23(4):360-365.

144. Zborowska B, Ell J, McGhee-Collett M, Scolyer R, McCluskey PJ. Progressive visual loss in a patient with presumed temporal arteritis despite treatment: how to make the diagnosis. Clin Experiment Ophthalmol. 2004;32(3):335-336.

145. Durso SC. Oral manifestations of disease. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J (eds). Harrison's Principles of Internal Medicine. 20th ed. New York, NY: McGraw-Hill; 2018.

146. Mock D, Chugh D. Burning mouth syndrome. Int J Oral Sci. 2010;2(1):1-4.

147. Zakrzewska JM, Forssell H, Glenny AM. Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev. 2012;5:1-26.

148. American Migraine Foundation. Migraine Triggers. Available at Last accessed June 15, 2021.

149. Aukerman G, Knutson D, Mise WF. Management of the acute migraine headache. Am Fam Physician. 2002;66(11):2123-2130.

150. Lança AJ. Herbal Medications: An Evidence-Based Review. Sacramento, CA: NetCE; 2019.

151. Levin M. Herbal treatment of headache. Headache. 2012;52(Suppl 2):76-80.

152. Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1-S59.

153. Shaik MM, Tan HL, Kamal MA, Gan SH1. Do folate, vitamins B6 and B12 play a role in the pathogenesis of migraine? The role of pharmacoepigenomics. CNS Neurol Disord Drug Targets. 2014;13(5):828-835.

154. Morey SS. Headache Consortium releases guidelines for use of CT or MRI in migraine work-up. Am Fam Physician. 2000;62(7):1699-1701.

155. Chopra R, Robert T, Watson DB. Non-pharmacological and pharmacological prevention of episodic migraine and chronic daily headache. W V Med J. 2012;108(3):88-91.

156. Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011;31(14):1428-1438.

157. Kelley NE, Tepper DE. Rescue therapy for acute migraine. Part 1: triptans, dihydroergotamine, and magnesium. Headache. 2012;52(1):114-128.

158. Kelley NE, Tepper DE. Rescue therapy for acute migraine. Part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache. 2012;52(3):467-482.

159. Valade D. Early treatment of acute migraine: new evidence of benefits. Cephalalgia. 2009;29(Suppl 3):15-21.

160. Robertson CE, Black DF, Swanson JW. Management of migraine headache in the emergency department. Semin Neurol. 2010;30(2):201-212.

161. DeMaagd G. The pharmacological management of migraine. Part 1: overview and abortive therapy. PT. 2008:33(7):404-416.

162. Institute for Clinical Systems Improvement. Diagnosis and Treatment of Headache. Available at Last accessed June 15, 2021.

163. Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008039.

164. Orr SL, Aubé M, Becker WJ, et al. Canadian Headache Society systemic review and recommendations on the treatment of migraine pain in emergency settings. Cephalagia. 2015;35(3):271-284.

165. Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: a systematic review. Headache. 2013;53(2):277-287.

166. Sumamo Schellenberg E, Dryden DM, Pasichnyk D, et al. Acute Migraine Treatment in Emergency Settings. Rockville, MD: Agency for Healthcare Research and Quality; 2012.

167. Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache. 2006;46(5):781-787.

168. Wilson JF. In the clinic: migraine. Ann Intern Med. 2007;147(9):ITC11ITC16.

169. Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine vs. subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010;56(1):1-6.

170. Shahien R, Saleh SA, Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. Acta Neurol Scand. 2011;123(4):257-265.

171. Maizels M, Geiger AM. Intranasal lidocaine for migraine: a randomized trial and open-label follow-up. Headache. 1999;39(8):543-551.

172. Klapper JA, Stanton JS. The emergency treatment of acute migraine headache: a comparison of intravenous dihydroergotamine, dexamethasone and placebo. Cephalalgia. 1991;11(Suppl 11):159-160.

173. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci. 1998;5(1):24-27.

174. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulphate rapidly alleviates headaches of various types. Headache. 1996;36(3):154-160.

175. Katzung BG. Histamine, serotonin and the ergot alkaloids. In: Katzung BG (ed). Basic and Clinical Pharmacology. 14th ed. New York, NY: McGraw-Hill; 2018: 277-299.

176. Lexicomp Online. Available at Last accessed June 10, 2018.

177. Diener HC, Bussone G, de Liano H. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan, and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24(11):947-954.

178. Ferrari MD, Roon KI, Lipton RB, Goasby PJ. Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668-1675.

179. Ephross SA, Sinclair SM. Final results from the 16-year Sumatriptan, Naratriptan, and Treximet Pregnancy Registry. Headache. 2014;54(7):1158-1172.

180. Rothrock JF. Migraine "chronification:" what you can do. Headache. 2009;49(1):155-156.

181. Loder EW, Rizzoli P. Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations. Headache. 2011;51(8):1336-1345.

182. DeMaagd G. The pharmacological management of migraine. Part 2: preventive therapy. PT. 2008:33(8):480-487.

183. Silberstein SD, Freitag FG. Preventative treatment of migraine. Neurology. 2003;60:S38-S44.

184. Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol. 2007;7:383-393.

185. Shapiro RE. Preventive treatment of migraine. Headache. 2012;52(Suppl 2):65-69.

186. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337-1345.

187. Modi S, Lowder DM. Medications for migraine prophylaxis. Am Fam Physician. 2006;73(1):72-78.

188. Mulleners WM, McCrory DC, Linde M. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia. 2015;35(1):51-62.

189. Rizzoli P, Loder EW. Tolerance and loss of beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanisms. Headache. 2011;51(8):1323-1335.

190. Centers for Disease Control and Prevention. Health, United States, 2015: With Special Feature on Racial and Ethnic Disparities. Available at Last accessed June 15, 2021.

191. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache and Pain. 2016;17(1):104.

192. Cao Y, Zheng OJ. Tonabersat for migraine prophylaxis: a systematic review. Pain Physician. 2014;17(1):1-8.

193. Sarrouilhe D, Dejean C, Mesnil M. Involvement of gap junction channels in the pathophysiology of migraine with aura. Front Physiol. 2014;5:78.

194. Martelletti P, Jensen RH, Antal A, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain. 2013;14:86.

195. U.S. Food and Drug Administration. Treating Migraines: More Ways to Fight the Pain. Available at Last accessed June 15, 2021.

196. Silberstein SD. Tonabersat, a novel gap-junction modulator for the prevention of migraine. Cephalalgia. 2009;29(Suppl 2):28-35.

197. Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG; Tonabersat TON-01-05 Study Group. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia. 2009;29(7):742-750.

198. Hegarty AM, Zakrzewska JM. Differential diagnosis for orofacial pain, including sinusitis, TMD, and trigeminal neuralgia. Dent Update. 2011;38(6):396-408.

199. Sudlow C. US guidelines on neuroimaging in patients with non-acute headache: a commentary. J Neurol Neurosurg Psychiatry. 2002;72(Suppl II):ii16-ii18.

200. Detsky ME, McDonald DR, Baerlocher MO, Tomlinson GA, McCrory DC, Booth CM. Does this patient with headache have a migraine or need neuroimaging? JAMA. 2006;296(10):1274-1283.

201. Sicuteri F. Dopamine, the second putative protagonist in headache. Headache. 1977;17(3):129-131.

202. Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia. 2007;27(11):1308-1314.

203. Davies P. What has imaging taught us about migraine? Maturitas. 2011;70(1):34-36.

204. Lakhan SE, Avramut M. Structural and functional neuroimaging in migraine: insight from three decades of research. Headache. 2013;53(1):46-66.

205. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52(6):930-945.

206. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry. 1960;23(1):23-32.

207. Ferguson M. Rhinosinusitis in oral medicine and dentistry. Aust Dent J. 2014;59(3):289-295.

208. Scully C. Oral and Maxillofacial Medicine: The Basis of Diagnosis and Treatment. 3rd ed. Edinburgh: Churchill Livingstone; 2013: 125-135.

209. Williams JW, Simel DL. Does this patient have sinusitis? Diagnosing sinusitis by history and physical examination. JAMA. 1993;270:1242-1246.

210. Pradhan AA, Bertels Z, Akerman S. Targeted nitric oxide synthase inhibitors for migraine. Neurotherapeutics. 2018;15(2):391-401.

211. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR. 2016;65(RR-3): 1-104.

212. Calhoun AH, Batur P. Combined hormonal contraceptives and migraine: an update on the evidence. Clev Clin J Med. 2017;84(8):631-638.

213. Sarrouilhe D, Dejean C, Mesnil M. Involvement of gap junction channels in the pathophysiology of migraine with aura. Front Physiol. 2014;5:78.

214. U.S. Food and Drug Administration. FDA Approves Novel Preventive Treatment for Migraine. Available at Last accessed June 15, 2021.

215. American Headache Society. Headache Toolbox: Menstrual Migraine. Available at Last accessed June 15, 2021.

216. Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: the American Headache Society evidence-based guidelines. Headache. 2016;56(7):1093-1106.

217. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20.

218. Friedman BW. Managing migraine. Ann Emerg Med. 2017;69(2):202-207.

219. Friedman BW, Cabral L, Adewunmi V, et al. Diphenhydramine as adjuvant therapy for acute migraine: an ED-based randomized clinical trial. Ann Emerg Med. 2016;67(1):32-39.

220. Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: a prospective observational cohort study. Cephalalgia. 2017;38(6):1081-1092.

221. Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123-2132.

222. Khan S, Olesen A, Ashina M. CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. Cephalalgia. 2017.

223. Schuster NM, Rapoport AM. Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache: a review.Clin Neuropharmacol. 2017;40(4):169-174.

224. Perloff MD, Berlin RK, Gillette M, Petersile MJ, Kurowski D. Gabapentin in headache disorders: what is the evidence? Pain Medicine. 2016;17(1):162-171.

225. U.S. Food and Drug Administration. Highlights of Prescribing Information: Ajovy (Fremanezumab-vfrm). Available at Last accessed June 14, 2021.

226. U.S. Food and Drug Administration. Highlights of Prescribing Information: Emgality (Galcanezumab-gnlm). Available at Last accessed June 14, 2021.

227. U.S. Food and Drug Administration. FDA Approves New Treatment for Adults with Migraine. Available at Last accessed June 14, 2021.

228. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60-68.

229. Ashina M. Migraine. N Eng J Med. 2020;383:1866-1876.

230. AHS Consensus Statement. The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice. Available at Last accessed June 14, 2021

231. Abu-Arafeh I, Razak S, Silvaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52:1088-1097.

232. Orr SL, Potter BK, Ma J, Colman I. Migraine and mental health in a population-based sample of adolescents. Canad J Neurol Sci. 2016;44:44-50.

233. Orr SL, Kabbouche MA, O'Brien HL, et al. Paediatric migraine: evidence-based management and future directions. Nat Rev Neurol. 2018;14:515-527.

234. American Academy of Neurology/American Headache Society. Practice Guideline Update: Acute Treatment of Migraine in Children and Adolescents, August 2019. Available at Last accessed June 14, 2021.

235. Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222-e2232.

236. U.S. Food and Drug Administration. FDA Approves First Treatment for Episodic Cluster Headache that Reduces the Frequency of Attacks. Available at Last accessed January 6, 2022.

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.